Reducing the pain and cost of rheumatoid arthritis

Liebeskind, Debra S.
January 2006
Employee Benefit News;Jan2006, Vol. 20 Issue 1, p42
This article discusses the cost of rheumatoid arthritis and its impact on employers. A detailed information on rheumatoid arthritis is given. The direct medical and drug costs of rheumatoid arthritis for employees and employers are discussed. Ways for employers to reduce the impact of the cost of rheumatoid arthritis are enumerated.


Related Articles

  • Rheumatoid Arthritis Carries High Costs for Employers.  // O&P Business News;5/1/2006, Vol. 15 Issue 9, p55 

    This article reports that rheumatoid arthritis is a major contributor to health care costs of employers, according to a study led by Ronald J. Ozminkowski, of the Cornell University Institute for Health and Productivity Studies. Ozminkowski and colleagues found that the average annual medical...

  • The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Jönsson, B.; Kobelt, G.; Smolen, J. // European Journal of Health Economics;Dec2007 Supplement 2, Vol. 8, p61 

    This paper presents data on international differences in use of TNF inhibitors. It is part of a study on burden and cost of RA, access to new therapies and the role of HTA in determining access and cost-effectiveness. United States has the fastest most extensive use of the new drugs, about three...

  • Patient access to rheumatoid arthritis treatments. Jönsson, Bengt; Kobelt, Gisela; Smolen, Josef // European Journal of Health Economics;Dec2007 Supplement 2, Vol. 8, p33 

    The article provides a review of the medical and economic perspective of the new drug for the treatment of rheumatic arthritis. It is stated that issues in the costs involved in the treatment have raised concerns as it raised tenfold in a short period. Questions on pricing and the importance of...

  • Specialty drug costs now make up half of the total cost of RA and hepatitis C care.  // Formulary;Jun2013, Vol. 48 Issue 6, p202 

    The article reports on topics which were discussed in a presentation which was given by Patrick Gleason of Prime Therapeutics during the 2013 annual meeting and expo of the Academy of Managed Care Pharmacy, which was held in April of 2013 in San Diego, California. In his presentation Gleason...

  • The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Kobelt, G.; Jönsson, B. // European Journal of Health Economics;Dec2007 Supplement 2, Vol. 8, p95 

    Within the series of articles investigating the burden of rheumatoid arthritis (RA), this paper reviews the methods used for economic assessment of the RA treatments by HTA agencies and other bodies involved in cost-effectiveness analysis and the current status of the field. The overall methods,...

  • Sticker Shock Over & Over Again. Moss, Marcy O'Koon // Arthritis Today;May/Jun2004, Vol. 18 Issue 3, p4 

    Talks about the safety of imported drugs in the U.S. Cost of rheumatoid arthritis medications; Effort of the U.S. Food and Drug Administration to assure the safety of imported drugs.

  • EMPLOYERS MOVE TO KEEP PROFIT FROM GOING UP IN SMOKE. DUNNING, MATT // Business Insurance;7/6/2015, Vol. 49 Issue 14, p0018 

    The article reports on smoking-cessation programs with incentives and banning of cigarettes by employers to curb employee smoking in the U.S. The initiative aims to combat added medical expenses from workers compensation claims and exposure to second-hand smoking as well as improve employees'...

  • More can be done to cut Rx costs.  // Business Insurance;3/1/2004, Vol. 38 Issue 9, p8 

    If there ever was a benefit program in need of cost management, it is prescription drug coverage. As much as group health care costs have risen over the past few years, the costs of prescription drugs have risen even more, with 15% to 20% annual increases quite common. In recent months, several...

  • Disease-modifying antirheumatic drugs prove most cost-effective in very early RA.  // Formulary;Feb2010, Vol. 45 Issue 2, p66 

    The article discusses research into the cost-effectiveness of using conventional disease-modifying anti-rheumatic drugs (DMARD) or early biologics in treating very early rheumatoid arthritis (RA). If RA is diagnosed and treated early, long-term remission may occur without the need for any...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics